Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Microbiol Infect. 2020 Feb 12;26(9):1207–1213. doi: 10.1016/j.cmi.2020.02.004

Figure 3: Simulation of the Genetic Algorithm-optimised Regimens for Coverage of 90% of Simulated Patients.

Figure 3:

The genetic algorithm was able to identify an optimised combination of meropenem + polymyxin B for the treatment of high (red) and low (blue) inoculum infections. Shaded regions represent the 90% prediction interval of the treatment based on previously published population pharmacokinetics in critically ill patients.[30, 46] To produce eradication in 90% of simulated subjects with a high inoculum (108 cfu/mL) infection, the optimised regimen was: Meropenem 17.8 g/day 2.5 h prolonged infusion q6h (with 22.2% of the total first day’s dose given at 0 h) + Polymyxin B 5.33 mg/kg/day 2 h prolonged infusion q8h (with 51.1% of the total first day’s dose given at 0 h). To produce eradication in 90% of simulated subjects with a low inoculum (106 cfu/mL) infection, the optimised regimen was: Meropenem 16.9 g/day 2.5 h prolonged infusion q5h (with 65.1% of the total first day’s dose given at 0 h) + Polymyxin B 4.74 mg/kg/day 2.5 h prolonged infusion q6h (with 33.6% of the total first day’s dose given at 0 h).